Liz Burton, PhD
@Liz_htx03
Followers
174
Following
247
Media
9
Statuses
69
Mom | Research | Taco enthusiast | Executive Director @MDAndersonNews - Views are my own.
Houston, TX
Joined October 2020
Roda Amaria, @PAscierto, @ProfCUBlankNKI , @ProfGLongMIA, Alex Menzies, @ProfRAScolyer, @HTawbi_MD, Michael Tetzlaff, Alex van Akkooi, @JenWargoMD
0
0
3
Honored & excited that the INMC is receiving the SITC 40th Anniversary Collaboration Award! Since 2016, this global effort has shaped melanoma care & sparked cross- cancer collaborations. Grateful to co lead w/ a tremendous team of leaders to make this shared vision possible!
Congratulations to Dr. Andres Salazar of @oncovir, along with the INMC, led by Dr. Elizabeth Burton of @MDAndersonNews, and the STAR Collaborative, led by Dr. Stephen Gottschalk of @StJude, recipients of 40th Anniversary Collaboration Awards. LEARN MORE: https://t.co/VQcfvkNGVe
1
5
16
Excited to see this work now out in JCO, important and unique long term data for the newest checkpoint combination. B7-H3 result could be practice informing & importantly targetable. Congrats to @Liz_htx03 for the incredible work to make this happen & Profs. Amaria & @JenWargoMD
Patients with advanced melanoma who received nivolumab + relatlimab before and after surgery had lasting results four years later. Biomarkers may help predict who benefits most. https://t.co/pxnMX5fEP9
#EndCancer
1
6
36
What an honor to present some of my PhD work to amazing colleagues and friends at the Bridges meeting this week in Naples. Incredible group & brilliant scientists sharing insights and perspectives.
Comprehensive and exciting overview of neoadjuvant PD-1+LAG-3 data in melanoma, lung, and beyond. @Liz_htx03 has done extensive biomarker analyses and highlights some familiar (B cells, IFN) and some novel (TIGIT, B7-H3) markers. B7-H3 is quite novel and potentially targetable!
1
1
13
Out now for #ESMO24! In #ISPY2.2, neoadjuvant Dato-DXd, followed by sequential CT w/ or w/o targeted therapy & optional early resection after each therapy block in pts w/ high-risk #BreastCancer, was superior to SOC in a subgroup of pts. @DrLauraEsserman
0
5
13
The International Neoadjuvant Melanoma Consortium (#INMC) meets for the 8th year running, so much progress & still much to consider, kicked off by @Liz_htx03 providing context to multiple neoadjuvant trial results in melanoma & other cancers #ESMO24
1
7
30
Great start to #ESMO24 with the International Neoadjuvant Melanoma Consortium meeting. @Liz_htx03 kicks us off showing us the progress in our field since the first meeting in 2016.
0
3
10
2/2 So immensely grateful for the support of my committee, colleagues, family, and dear friends - flying in from San Francisco (@DrBetofMDPhD), @HTawbi_MD bringing churros and hosting an amazing celebration dinner - there are no words for how grateful I am for each of you.
2
0
11
1/2 And PhD done! What a crazy couple of years. Big big thank you to my amazing supervising professor @ChrisRFrei , the TS PhD faculty, Dr Roda Amaria @MDAndersonNews and the support of my amazing international committee members @PAscierto and @ProfCUBlankNKI
4
2
28
Great idea to add for future meeting. Work led by @DrMCabanillas @MDAndersonNews adding #neoadjuvant #immunotherapy to BRAF targeted therapy has shown great promise in anaplastic #thyroid #cancer!
1
2
7
The beauty of Napoli only to be outdone by the incredible scientific discussions pushing the frontiers of #neoadjuvant #immunotherapy across #Cancer at INNOVATE, hands down the best meeting of 2024 led by @Liz_htx03 @PAscierto @ProfCUBlankNKI!
1
4
25
(2/2) Representation from multiple disciplines in academia, ESMO & SITC presidents (@curijoey & @EmensLeisha), and pharma. Much progress made, and much more to come. Many thanks to our speakers & session chairs, for their expertise, participation, and leadership!
0
2
12
(1/2) What a humbling opportunity to organize and co-chair the first Intl Neoadjuvant Immunotherapy Across Cancers (INNOVATE) mtg in Naples with @PAscierto & @ProfCUBlankNKI bringing together critical leaders for 2 days of deep discussion.
5
9
41
Inspiring discussion re; #neoadjuvant #melanoma with colleagues from International Neoadjuvant Melanoma Consortium (INMC). Massive positive impact on patient outcomes. Areas to refine - how much surgery is needed, who needs what #immunotherapy & for how long, does #pathology
1
8
125
Can’t imagine any other way to kick off #ASCO24! Incredible collaborations and multi disciplinary discussion today. Exciting things in melanoma and across cancers with neoadjuvant IO!
And we’re off!! @Liz_htx03 from @MDAndersonNews is kicking off #ASCO24 with the 2024 Neoadjuvant Melanoma Constorium meeting! What an exciting year for neoadjuvant melanoma therapy with the #NADINA trial being presented by @ProfCUBlankNKI as a Plenary Session! @OncoAlert
0
0
6
3P Solutions - The first edition of the I.N.N.O.V.A.T.E - Neoadjuvant immunotherapy across cancers @3PSolution @PAscierto @ProfCUBlankNKI @Liz_htx03
https://t.co/q89fdxkbXU
#Cancer #CancerResearch #HealthcareAdvancements #ImmunoTherapy #OncoDaily #Oncology
0
3
15
Dealing with Brain Metastases? Multidisciplinary care approach is a MUST! @HTawbi_MD at @MDAndersonNews is highlighting this important effort and its incredible impact on patient care (more than 1500 seen in our multidisciplinary Brain Mets clinic to date! ) #EADO2024
0
4
12
Excited to cochair this mtg with @PAscierto and @ProfCUBlankNKI - bringing together amazing folks for neoadjuvant immunotherapy collaborations!
The first edition of the I.N.N.O.V.A.T.E congress will be held in Naples on July 11th and 12th, 2024 - @3PSolution
@PAscierto @ProfCUBlankNKI @Liz_htx03
https://t.co/kFQ4B7cS1T
#Biomarkers #Cancer #Immunotherapy #OncoDaily #Oncology #CancerCare
0
1
10
How to approach the treatment of patients with brain metastases? IMO in only one way- multidisciplinary care with a dedicated clinic, providing excellent patient care and a research platform! @HTawbi_MD sharing the @MDAndersonNews experience and success at #melanomabridge2023
0
2
6
Neoadjuvant therapy is increasingly becoming SOC for #melanoma. @ProfCUBlankNKI proposing a modified paradigm for agent selection based on interferon signature- the main question- what do we use for IFN low? Triplet therapy seems very aggressive in this setting but IF tox is
0
6
11